Facebook
Twitter
LinkedIn

Eric Easom

Mr. Easom has over 29 years of leadership experience in the biotechnology and pharmaceutical industry and has spent the last 15 years focused on bringing innovation to address significant unmet needs in infectious diseases, focused on the developing world. Currently Mr. Easom is the Founder, President and CEO of AN2 Therapeutics, an R&D-stage biotech focused on anti-infectives. He also serves on the Board of Directors for the Chagas Disease Foundation, Resilient Biotics and an advisor for the California Life Sciences Institute. Previously, Mr. Easom spent 9 years at the highly successful Anacor Pharmaceuticals which was acquired by Pfizer for $5.2B in 2016. During his tenure, he led Anacor’s R&D on neglected disease programs that achieved global prominence, working in close partnership with the Bill and Melinda Gates Foundation, the Wellcome Trust, The University of Georgia (Tarleton Lab), Medicines for Malaria Venture, Global Alliance for Veterinary Medicine, Drugs for Neglected Disease initiative, GlaxoSmithKline (GSK), Eli Lilly & Company, the University of California San Francisco (Rosenthal, McKerrow and Sakanari Labs), Colorado State University (Slayden and Lenaerts’ Labs), DTRA, Walter Reed, the London School of Hygiene and Tropical Medicine (Croft Lab), TB Alliance, Anti-Wolbachia Consortium, One World Health and numerous other academic partners. The Anacor team raised $80M in funding and discovered over a dozen potentially transformational medicines for diseases such as malaria, tuberculosis, river blindness, cryptosporidiosis and trypanosome diseases including Chagas disease, African sleeping sickness and leishmaniasis. Mr. Easom also served on the Board of Directors for a Seattle-based nonprofit, the Infectious Disease Research Institute, from 2007-2014, serving as Chairman from 2009-2013. He has served as a guest lecturer at the University of Washington, Seattle University and San Jose State University. The majority of his early career was at Eli Lilly and Company, followed by stints at McKesson and biotechs MedImmune and InteKrin Therapeutics.